Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.81 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.81 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149826 | 1.00 | ADRB2 (0.81) | ADRB2CHRM3ADRA1DADRB1 | |
| SCHEMBL4149718 | 0.94 | ADRB2 (0.91) | ADRB2CHRM3ADRA1DADRB1 | |
| SCHEMBL4149727 | 0.94 | ADRB2 (0.91) | ADRB2CHRM3ADRA1DADRB1 | |
| SCHEMBL4151177 | 0.90 | ADRB2 (1.00) | ADRB2CHRM3ADRA1DADRB1 | |
| SCHEMBL4151186 | 0.90 | ADRB2 (1.00) | ADRB2CHRM3ADRA1DADRB1 | |
| SCHEMBL4145062 | 0.88 | ADRB2 (0.83) | ADRB2CHRM3 | |
| SCHEMBL4149830 | 0.85 | ADRB2 (0.59) | ADRB2CHRM3ADRA1DADRB1 | |
| SCHEMBL4144496 | 0.83 | ADRB2 (0.78) | ADRB2CHRM3 | |
| SCHEMBL14411783 | 0.83 | ADRB2 (0.70) | ADRB2CHRM3ADRA1DADRB1 | |
| SCHEMBL4156828 | 0.82 | ADRB2 (0.71) | ADRB2CHRM3ADRA1DADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | claimed |
| EP-1999107-A2 | AMINE DERIVATIVES | Pfizer Limited (GB) | 2008-12-10 | — | — | EP | claimed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | claimed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | claimed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-1999107-A2 | AMINE DERIVATIVES | Pfizer Limited (GB) | 2008-12-10 | — | — | EP | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | ADRB2 93/4885CHRM3 169/4885ADRA1D 51/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | ADRB2 93/4885CHRM3 169/4885ADRA1D 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.